Docetaxel is a potent cytotoxic drug in the treatment of advanced breast cancer

Acta Clinica Belgica

Volumn 53, Issue 4, 1998, Pages 264-269

  Van Vaerenbergh, W ^a   Paridaens, R ^a,b   Thomas, J ^a   Wildiers, J ^a   Van Oosterom, A ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE DERIVATIVE; ANTHRAQUINONE; CYTOTOXIC AGENT; DOCETAXEL; PACLITAXEL; TAXANE DERIVATIVE;

ADULT; AGED; ARTICLE; BONE MARROW SUPPRESSION; BREAST CANCER; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; DRUG EFFICACY; DRUG POTENCY; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MICROTUBULE ASSEMBLY; MITOSIS INHIBITION; NEUTROPENIA;

ADULT; AGED; ANTHRAQUINONES; ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BREAST NEOPLASMS; CELL DIVISION; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MICROTUBULES; MIDDLE AGED; MITOSIS; NEOPLASM STAGING; NEUTROPENIA; PACLITAXEL; REMISSION INDUCTION; SURVIVAL RATE; TAXOIDS; TUBULIN;

EID: 0031755865     PISSN: 00015512     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (11)

1. Lavelle F, Bissery MC, Combeau C, et al. Preclinical evaluation of docetaxel (Taxotere). Semin Oncol. 1995; 22, Suppl. 4: 3-16.
2. Bissery MC, Nohynek G, Sanderink GJ, Lavelle F. Docetaxel (Taxotere) : a review of preclinical and clinical experience. Part I: preclinical experience. Anti-Cancer Drugs. 1995; 6: 339-368.
3. Ten Bokkel Huinink WW, Prove AM; Piccart M, et al. A phase II trial with docetaxel (Taxotere) in second line treatment with chemotherapy for advanced breast cancer. A study of the EORTC Early Clinical Trials Group. Ann Oncol. 1994; 5: 527-532
4. Eisenhauer EA, Trudeau M. An overview of phase II studies of docetaxel in patients with metastatic breast cancer. Eur J Cancer. 1995; 31A, Suppl. 4: S11-S13.
5. Van Oosterom AT, Schrijvers D. Docetaxel (Taxotere): a review of preclinical and clinical experience. Part II: clinical experience. Anti-Cancer Drugs. 1995; 6: 356-368.
6. Ravdin PM, Valero V. Review of docetaxel (Taxotere), a highly active new agent for the treatment of metastatic breast cancer. Semin Oncol. 1995; 22: 17-2 1.
7. Van Oosterom AT. Docetaxel (Taxotere) : an effective agent in the management of second-line breast cancer. Semin Oncol. 1995; 22: 22-28.
8. Ravdin PM, Burris III HA, Cook G, et al. Phase II trial of docetaxel in advanced anthracycline-resistant or anthracenedione-resistant breast cancer. J Clin Oncol. 1995; 13: 2879-2885.
9. Valero V, Holmes FA, Walters RS. Phase II trial of docetaxel : a new, highly effective antineoplastic agent in the management of patients with anthracycline-resistant metastatic breast cancer. J Clin Oncol. 1995; 13: 2886-2894.
10. Fumoleau P, Chevallier B, Kerbrat P, et al. Current status of Taxotere (docetaxel) as a new treatment in breast cancer. Breast Cancer Res Treat. 1994; 33: 39-46.
11. Chevallier B, Fumoleau P, Kerbrat P, et al. Docetaxel is a major cytotoxic drug for the treatment of advanced breast cancer : a phase II trial of the Clinical Screening Cooperative Group of the European Organization for Research and Treatment of Cancer. J Clin Oncol. 1995; 13: 314-322.